News
An optic nerve that has an injury cannot be fixed, so usually, if there is vision loss from ischemic optic neuropathy, it is permanent. Those with badly damaged optic nerves usually can still see ...
Source Reference: Cai CX, et al "Semaglutide and nonarteritic anterior ischemic optic neuropathy" JAMA Ophthalmol 2025; DOI: 10.1001/jamaophthalmol.2024.6555. Secondary Source JAMA Ophthalmology ...
Researchers found that among semaglutide users, the incidence rate of nonarteritic anterior ischemic optic neuropathy was 14.5 per 100,000 person-years. HealthDay News — For individuals with ...
Ischemic optic neuropathy is a condition that causes sudden vision loss due to a lack of blood flow to the optic nerve. Ischemic optic neuropathy is most common in people age 50 and older.
The deep learning system distinguishes IIH, NAION, and healthy eyes with 93.6% accuracy, aiding in resource-limited settings.
WEDNESDAY, July 3, 2024 (HealthDay News) -- Semaglutide is associated with nonarteritic anterior ischemic optic neuropathy (NAION) among patients with type 2 diabetes (T2D) and those with ...
A deep learning system achieved an accuracy of more than 90% in distinguishing arteritic from nonarteritic anterior ischemic optic neuropathy using only color fundus images, according to a study ...
Anatomy of the eye and how anterior ischemic optic neuropathy (AION) presents clinically compared to healthy vision. Depositphotos. The exact mechanism that causes NAION isn’t known.
Researchers say they have uncovered a link between semaglutide — the active ingredient in Ozempic and Wegovy — and the eye disorder non-arteritic anterior ischemic optic neuropathy.
4mon
Daily Express US on MSNOzempic and Zepbound linked to rare eye conditions that could cause blindness - MSNSeven of these patients developed non-arteritic anterior ischemic optic neuropathy (NAION), a condition where reduced blood flow to the optic nerve can cause sudden and irreversible blindness.
Nonarteritic Anterior Ischemic Optic Neuropathy Increased With Semaglutide Publish Date February 28, 2025 Increase in NAION associated with semaglutide use among individuals with type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results